KeyNeurotek Pharmaceuticals Reports Breakthrough In The Treatment Of Patients With Severe Traumatic Brain Injury In A Phase IIa Study
12/16/2009 11:31:06 AM
More...
|
KeyNeurotek Pharmaceuticals Completes € 8.2 Million ($ 10.8 Million) Series C Financing Round
4/7/2009 11:33:55 AM
More...
|
KeyNeurotek Pharmaceuticals Concludes Patient Recruitment In A Phase IIa Traumatic Brain Injury Study With KN38-7271 On Schedule
12/15/2008 2:41:43 PM
More...
|
KeyNeurotek Pharmaceuticals Reports Breakthrough Discovery in Huntington's Disease
7/10/2008 1:34:31 PM
More...
|
KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist
5/8/2008 2:05:21 PM
More...
|
KeyNeurotek Pharmaceuticals Initiates Phase I Study With Canabinoid Receptor Agonist
11/8/2007 2:46:08 PM
More...
|